Search - tctmd.com

Displaying 841 - 860 of 1484

Sort: Relevancy | Date

News Daily News

Un Estudio Sugiere que la Revascularización de Arterias No Causantes Mejora el Estado de Salud de Pacientes STEMI

Todd Neale

November 04, 2015

News Daily News

Study Suggests Nonculprit Revascularization Enhances Health Status of STEMI Patients

Todd Neale

November 04, 2015

News Daily News

Mortalidad Intrahospitalaria Más Alta cuando se Liberan IABP durante la Realización de PCI

Todd Neale

November 04, 2015

News Daily News

In-hospital Mortality Higher When IABPs Deployed During PCI

Todd Neale

November 04, 2015

News Daily News

Younger Women With STEMI More Likely Than Men to Die In-Hospital

L.A. McKeown

October 28, 2015

News Daily News

Younger Women With STEMI More Likely Than Men to Die In-Hospital

L.A. McKeown

October 28, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Todd Neale

October 26, 2015

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

Todd Neale

October 26, 2015

News Industry News

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

October 20, 2015

News Conference News TCT 2015

Nordic-Baltic Bifurcation III: Kissing Balloon Dilatation Does Not Reduce MACE at 5 Years

October 16, 2015

$Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!$

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry

October 15, 2015

$Miscellaneous Emerging Technologies 2: The Neovasc Reducer System for Refractory Angina$

Presentation TCT 2015

Miscellaneous Emerging Technologies 2: The Neovasc Reducer System for Refractory Angina

Presenter: Greg L. Kaluza, Joachim Schofer, Timothy D. Henry

October 15, 2015

News Conference News TCT 2015

Initial Surgical AVR Improves Long-term Outcomes in Asymptomatic Patients With Severe AS

October 15, 2015

News Conference News TCT 2015

RIVER-PCI: No Advantage to Ranolazine in Patients With Incomplete Revascularization

Yael L. Maxwell

October 13, 2015

News Conference News TCT 2015

PLATFORM: FFRCT Reduces Costs Compared With Invasive Coronary Angiography

October 13, 2015

News Industry News

Medical Therapy With Ranolazine Did Not Reduce Adverse Events In Patients With Persistent Untreated Heart Artery Blockages After Percutaneous Coronary Intervention

October 13, 2015

News Conference News TCT 2015

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

October 13, 2015

News Industry News

Assessing Fractional Flow Reserve Using Computed Tomography Shown To Reduce Costs in Patients With Chest Pain

October 13, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

Advertisement

Un Estudio Sugiere que la Revascularización de Arterias No Causantes Mejora el Estado de Salud de Pacientes STEMI

Study Suggests Nonculprit Revascularization Enhances Health Status of STEMI Patients

Mortalidad Intrahospitalaria Más Alta cuando se Liberan IABP durante la Realización de PCI

In-hospital Mortality Higher When IABPs Deployed During PCI

Younger Women With STEMI More Likely Than Men to Die In-Hospital

Younger Women With STEMI More Likely Than Men to Die In-Hospital

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

Nordic-Baltic Bifurcation III: Kissing Balloon Dilatation Does Not Reduce MACE at 5 Years

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Miscellaneous Emerging Technologies 2: The Neovasc Reducer System for Refractory Angina

Initial Surgical AVR Improves Long-term Outcomes in Asymptomatic Patients With Severe AS

RIVER-PCI: No Advantage to Ranolazine in Patients With Incomplete Revascularization

PLATFORM: FFRCT Reduces Costs Compared With Invasive Coronary Angiography

Medical Therapy With Ranolazine Did Not Reduce Adverse Events In Patients With Persistent Untreated Heart Artery Blockages After Percutaneous Coronary Intervention

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

Assessing Fractional Flow Reserve Using Computed Tomography Shown To Reduce Costs in Patients With Chest Pain

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content